Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients

Study of Statins' Effect on Serum IgG, IgA Ang IgM Level in Chronic Hemodialysis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01305317

Enrollment

Registered

2011-02-28

Start date

2007-01-31

Completion date

2010-01-31

Last updated

2011-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

Statin

Brief summary

This is double blind randomized controlled trial on the statins effects on serum IgG, IgA and IgM level in chronic hemodialysis patients in Bandarabbas

Detailed description

This study is a randomized controlled trial of statins effect on serum IgG, IgA and IgM level on chronic hemodialysis patients in Bandarabbas. The study is carried out in Hormozgan, Iran. Seventy four patient were randomized either to receive atorvastatin in addition of usual treatment or not. The primary outcomes were serum IgG,IgA and IgM level. The secondary outcome was drug side effects.

Interventions

DRUGLipitor

Atorvastatin 20mg daily for 6 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All chronic hemodialysis patients attending Shahid Mohammadi hospital during the study period * Accepting to participate in the study

Exclusion criteria

* Refusing to participate in the study

Design outcomes

Primary

Measure	Time frame
Serum IgG, IgA and IgM level	6 months

Secondary

Measure	Time frame
Drug side effects	6 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026